IPO & Public Markets

A deep dive into Phaos Technology's 20-F filing reveals the stark contrast between public market capitalization and deep-tech commercialization hurdles.

HighLevel's appointment of Grubhub founder Matt Maloney to its board signals a strategic maturation as the $1 billion AI platform eyes enterprise-grade scale.

A recent Nasdaq deficiency notice for Singapore's CytoMed Therapeutics highlights the intense market pressures facing pre-revenue biotechs today.

A sharp rise in September CUSIP identifier requests points to an unfreezing IPO pipeline and strategic corporate debt issuance ahead of an active fourth quarter.

GOA Therapeutics is combining venture backing and institutional placements with retail crowdfunding as part of a $300 million strategy to fund its alcohol poisoning antidote candidate.

The SPAC market has grown up. Bluerock's latest $172.5 million vehicle reveals how structured capital is quietly fueling the next wave of enterprise innovation.

Payward's xStocks platform promises global retail investors pre-IPO access to Ōura. But the fine print reveals high fees and synthetic ownership.

ADARx Pharmaceuticals just executed one of 2026's largest biotech debuts. Here is why institutional capital and AbbVie are betting big on the siRNA frontier.

Susan Powell investigates The Oak Companies' corporate reorganization, unpacking the hidden costs of using retail equity to retire legacy fund debt.

As Recludix readies for the Oppenheimer showcase, its Sanofi-partnered STAT6 inhibitor signals a structural shift from biologics to oral small molecules.

Dillard's is swapping Wall Street for Dallas, marking a major victory for the Texas Stock Exchange and signaling a broader flight from Delaware.

A new partnership between Grantd and Collective Liquidity aims to unlock billions in illiquid stock, transforming how advisors and employees manage pre-IPO wealth.

Alterome Therapeutics brings on a heavy-hitting CFO in Johanna Mylet, who guided Poseida to an IPO and Roche acquisition. What does this signal for its future?

A century-old Hawaiian institution is going public. We look beyond the financials to see what ASB's Wall Street debut means for its community-first mission.

Interpace Biosciences is engineering its stock for a Nasdaq uplist, but is this financial maneuver a path to sustained growth or a classic warning sign?

Avenzo Therapeutics' new CHRO hire is more than a personnel move; it's a critical piece of a master plan for a public debut and oncology market disruption.

With wins from the Cerebras and SpaceX IPOs, Open Doors Partners hires Ravi Chiruvolu to deepen its expertise in a pivotal moment for private markets.

MDB Capital celebrates a string of successful IPOs but reports a staggering $16.1M loss, putting its unique 'public venture' model under intense scrutiny.

RECONOVA's massively oversubscribed IPO met a cool reception on its first day, signaling a new era where AI firms must prove profitability, not just potential.

A new $105M SPAC enters the fray. We examine its veteran leadership, its cross-sector strategy, and what it takes to win in today's SPAC market.